In this new series, we want to take a deep dive into the inspiring work of Huntington’s disease associations across Europe.
🇮🇸 Starting with Iceland, where the local HD Association is making a remarkable difference through innovative projects, strong community ties and ongoing advocacy for families affected by Huntington’s disease.
In this article about SOM3355, Astri Arnesen and Dina de Sousa explain what happened in the clinical trial, what’s next for the Phase 3 clinical trial, and what SOM Biotech has to say about this important step toward a potential new treatment for Huntington’s disease.
In September 24th, the company UniQure announced the results of its clinical trial after 36 months with AMT-130, a gene therapy for Huntington’s disease (HD).
In this article, we break down this information, explaining what the data shows, why it matters, and what they could mean for the future of Huntington’s disease research.